Literature DB >> 34250142

Estimation of the lower limits for feasible Ra-223 SPECT imaging: a Monte Carlo simulation study.

Akihiko Takahashi1, Hibiki Ueno2, Shingo Baba3, Masayuki Sasaki1.   

Abstract

OBJECTIVES: Ra-223 is a promising radionuclide for the treatment of skeletal metastases in castration-resistant prostate cancer patients. This study aims to estimate the lower limits for feasible Ra-223 single-photon emission computerized tomography (SPECT) imaging using a Monte Carlo simulation study.
METHODS: The SPECT images were produced on a homemade code: the Monte Carlo simulation of electrons and photons for SPECT (MCEP-SPECT). The National Electrical Manufacturers Association (NEMA) phantom with six hot spheres of diameters of 37, 28, 22, 17, 13, and 10 mm installed inside, was used. The background activity concentration was 0.6 kBq/mL, and the ratios of hot concentrations to the background (R HB) were 25, 20, 15, 10, and 5. When R HB was 15, the background concentrations of 1.5, 0.9, 0.3, and 0.15 kBq/mL were also tested. The energy window was 84 keV±10%. The number of projections was 60/360°, and the acquisition time was 60 s per projection. Two kinds of collimators: middle-energy general-purpose (MEGP) and high-energy general-purpose (HEGP), were examined. The SPECT images were evaluated based on two quantitative indexes: contrast-to-noise ratio (CNR) for detectability and contrast recovery coefficient (CRC) for quantitative accuracy.
RESULTS: The CRC for the HEGP collimator was 35-40%, while the CRC for the MEGP collimator was 25-30%. The CNRs for the MEGP collimator were larger than those for the HEGP collimator. The CNRs of the hot spheres with diameters less than 22 mm were lower than 5.0 for both collimators, when R HB and the background concentration were 15 and 0.6 kBq/mL, respectively. Based on the obtained results, it was estimated that the lower limit of R HB for the detection of the hot sphere with a diameter of 37 mm would be approximately 20 if the background concentration is 0.05 kBq/mL.
CONCLUSIONS: The MEGP collimator is superior in terms of detectability, while the HEGP collimator is superior in terms of quantitative accuracy. When the lesion size is small, the MEGP collimator may be favorable. Based on these results, the estimated lower limit of the activity concentration would be approximately 1 kBq/mL if the background concentration is 0.05 kBq/mL for a large lesion.
© 2021 mums.ac.ir All rights reserved.

Entities:  

Keywords:  Bone scintigraphy; Monte Carlo simulation Radionuclide therapy; Radium-223

Year:  2021        PMID: 34250142      PMCID: PMC8255527          DOI: 10.22038/AOJNMB.2021.54386.1372

Source DB:  PubMed          Journal:  Asia Ocean J Nucl Med Biol        ISSN: 2322-5718


  17 in total

1.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

2.  Determination of photon emission probabilities for the main gamma-rays of ²²³Ra in equilibrium with its progeny.

Authors:  L Pibida; B Zimmerman; R Fitzgerald; L King; J T Cessna; D E Bergeron
Journal:  Appl Radiat Isot       Date:  2015-03-12       Impact factor: 1.513

3.  A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.

Authors:  Sarah J Chittenden; Cecilia Hindorf; Christopher C Parker; Valerie J Lewington; Brenda E Pratt; Bernadette Johnson; Glenn D Flux
Journal:  J Nucl Med       Date:  2015-07-16       Impact factor: 10.057

4.  Dosimetry of 223Ra-chloride: dose to normal organs and tissues.

Authors:  Michael Lassmann; Dietmar Nosske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-11       Impact factor: 9.236

5.  Feasibility and limitations of quantitative SPECT for 223Ra.

Authors:  Johan Gustafsson; Emilia Rodeño; Pablo Mínguez
Journal:  Phys Med Biol       Date:  2020-04-20       Impact factor: 3.609

6.  A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.

Authors:  Massimiliano Pacilio; Guido Ventroni; Bartolomeo Cassano; Pasquale Ialongo; Leda Lorenzon; Elisabetta Di Castro; Federica Recine; Cora N Sternberg; Lucio Mango
Journal:  Ann Nucl Med       Date:  2015-11-27       Impact factor: 2.668

7.  Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.

Authors:  Massimiliano Pacilio; Guido Ventroni; Giuseppe De Vincentis; Bartolomeo Cassano; Rosanna Pellegrini; Elisabetta Di Castro; Viviana Frantellizzi; Giulia Anna Follacchio; Tatiana Garkavaya; Leda Lorenzon; Pasquale Ialongo; Roberto Pani; Lucio Mango
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-13       Impact factor: 9.236

8.  Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.

Authors:  Keisuke Yoshida; Tomohiro Kaneta; Shoko Takano; Madoka Sugiura; Tsuyoshi Kawano; Ayako Hino; Tou Yamamoto; Kazuya Shizukuishi; Masato Kaneko; Christian Zurth; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2016-06-07       Impact factor: 2.668

9.  223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification.

Authors:  Nadia Benabdallah; Michela Bernardini; Marta Bianciardi; Claire de Labriolle-Vaylet; Didier Franck; Aurélie Desbrée
Journal:  EJNMMI Res       Date:  2019-02-21       Impact factor: 3.138

10.  Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience.

Authors:  Yoshiki Owaki; Tadaki Nakahara; Takeo Kosaka; Junichi Fukada; Atsuhiro Kumabe; Akira Ichimura; Mikoto Murakami; Kiyotaka Nakajima; Masahiro Fukushi; Kazumasa Inoue; Mototsugu Oya; Masahiro Jinzaki
Journal:  EJNMMI Res       Date:  2017-10-03       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.